{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:50:22Z","timestamp":1771361422206,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bioorg.2023.106998","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:34:10Z","timestamp":1701124450000},"page":"106998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor"],"prefix":"10.1016","volume":"143","author":[{"given":"Hua","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106998_b0005","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/pr.58.4.9","article-title":"The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors","volume":"58","author":"N.Z. Lu, S.E. Wardell, K.L. Burnstein, D. Defranco, P.J. Fuller, V. Giguere, R.B. Hochberg, L. McKay, J.M. Renoir, N.L. Weigel, E.M. Wilson, D.P. McDonnell, J.A. Cidlowski, International union of pharmacology. LXV","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2023.106998_b0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0083-6729(08)60938-3","article-title":"Regulation of androgen action","volume":"55","author":"Roy","year":"1999","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bioorg.2023.106998_b0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/biom11040492","article-title":"Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review","volume":"11","author":"Kim","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2023.106998_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114112","article-title":"Targeting androgen receptor degradation with PROTACs from bench to bedside","volume":"158","author":"Jia","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2023.106998_b0025","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/ijms22042124","article-title":"An overview of next-generation androgen receptor-targeted therapeutics in development for the treatment of prostate cancer","volume":"22","author":"Mohler","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2023.106998_b0030","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2023.106998_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2023.106998_b0040","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/pros.22674","article-title":"Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer","volume":"73","author":"Guerrero","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2023.106998_b0045","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2023.106998_b0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2460\/javma.2001.218.1275","article-title":"Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy","volume":"218","author":"Sirinarumitr","year":"2001","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.bioorg.2023.106998_b0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/1389557033488196","article-title":"Steroid 5alpha-reductase inhibitors","volume":"3","author":"Flores","year":"2003","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106998_b0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pros.10340","article-title":"Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line","volume":"58","author":"Lazier","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2023.106998_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.aquatox.2012.12.003","article-title":"Mode of action of human pharmaceuticals in fish: the effects of the 5-alpha-reductase inhibitor, dutasteride, on reproduction as a case study","volume":"129","author":"Margiotta-Casaluci","year":"2013","journal-title":"Aquat. Toxicol."},{"key":"10.1016\/j.bioorg.2023.106998_b0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2023.106998_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.maturitas.2009.03.008","article-title":"Mechanism of androgen receptor action","volume":"63","author":"Li","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.bioorg.2023.106998_b0080","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2023.106998_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2023.106998_b0090","first-page":"161","article-title":"Testosterone deficiency: a historical perspective, Asian","volume":"16","author":"Nieschlag","year":"2014","journal-title":"J. Androl."},{"key":"10.1016\/j.bioorg.2023.106998_b0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/scientificamerican0295-76","article-title":"The history of synthetic testosterone","volume":"272","author":"Hoberman","year":"1995","journal-title":"Sci. Am."},{"key":"10.1016\/j.bioorg.2023.106998_b0100","unstructured":"W.W. Xue, Z.B. Xi, Y.Z. Wang, A preparation method of testosterone enanthate. 2012. CN102558267A."},{"key":"10.1016\/j.bioorg.2023.106998_b0105","series-title":"Dictionary of drugs: chemical data, structures and bibliographies","author":"Elks","year":"1990"},{"key":"10.1016\/j.bioorg.2023.106998_b0110","unstructured":"Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 716\u2013. ISBN 978-3-88763-075-1."},{"key":"10.1016\/j.bioorg.2023.106998_b0115","unstructured":"Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 402\u2013412, 460\u2013467, 193\u2013194. ISBN 978-0-9828280-1-4."},{"key":"10.1016\/j.bioorg.2023.106998_b0120","unstructured":"S. Zhibin, Z. Youkang, T. Duanjian. Method for the catalytic synthesis of phenylpropionate derivatives by ionic liquids. 2019. CN109678718A."},{"key":"10.1016\/j.bioorg.2023.106998_b0125","unstructured":"G.A. Hughes, H. Smith. Synthesis of 13-alkyl-gon-4-ones. 1976. US3959322A."},{"key":"10.1016\/j.bioorg.2023.106998_b0130","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1021\/acs.orglett.1c02702","article-title":"Benzyne-mediated esterification reaction","volume":"23","author":"Zhao","year":"2021","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2023.106998_b0135","doi-asserted-by":"crossref","unstructured":"Martindale: The Complete Drug Reference Brayfield Alison (Ed) Martindale: The Complete Drug Reference \u00a3459 4,688pp Pharmaceutical Press 9780857111395 0857111396. Emerg. Nurse. 22 (2014) 12.","DOI":"10.7748\/en.22.5.12.s13"},{"key":"10.1016\/j.bioorg.2023.106998_b0140","unstructured":"J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 345\u2013. ISBN 978-1-4757-2085-3."},{"key":"10.1016\/j.bioorg.2023.106998_b0145","unstructured":"Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 293\u2013. ISBN 978-3-88763-075-1."},{"key":"10.1016\/j.bioorg.2023.106998_b0150","unstructured":"I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 91\u2013. ISBN 978-94-011-4439-1."},{"key":"10.1016\/j.bioorg.2023.106998_b0155","doi-asserted-by":"crossref","unstructured":"V. Selak, C. Farquhar, A. Prentice, A. Singla, Danazol for pelvic pain associated with endometriosis, Cochrane Database Syst. Rev. (2007) Cd000068.","DOI":"10.1002\/14651858.CD000068.pub2"},{"key":"10.1016\/j.bioorg.2023.106998_b0160","unstructured":"Eric J. Thomas; John Rock (6 December 2012). Modern Approaches to Endometriosis. Springer Science & Business Media. pp. 239\u2013256. ISBN 978-94-011-3864-2."},{"key":"10.1016\/j.bioorg.2023.106998_b0165","unstructured":"Howard W. Jones; John A. Rock (10 July 2015). Te Linde's Operative Gynecology. Wolters Kluwer Health. pp. 1327\u20131330. ISBN 978-1-4963-1521-2."},{"key":"10.1016\/j.bioorg.2023.106998_b0170","unstructured":"Aurel Lupulescu (24 October 1990). Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 103\u2013. ISBN 978-0-8493-5973-6."},{"key":"10.1016\/j.bioorg.2023.106998_b0175","unstructured":"Albert Altchek; Liane Deligdisch; Nathan Kase (4 September 2003). Diagnosis and Management of Ovarian Disorders. Academic Press. pp. 376\u2013. ISBN 978-0-08-049451-7."},{"key":"10.1016\/j.bioorg.2023.106998_b0180","unstructured":"Y.B. Teng, B. Niu, X.Q. Hang. A new preparation method of danazol. 2022. CN114409724A."},{"key":"10.1016\/j.bioorg.2023.106998_b0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0303-7207(86)90132-2","article-title":"Characteristics of the interaction of the antiandrogen flutamide with the androgen receptor in various target tissues","volume":"44","author":"Simard","year":"1986","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.bioorg.2023.106998_b0190","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Flutamide","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106998_b0195","unstructured":"James Leonard Gulley (2011). Prostate Cancer. Demos Medical Publishing. pp. 81\u2013. ISBN 978-1-935281-91-7."},{"key":"10.1016\/j.bioorg.2023.106998_b0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/00397910500464848","article-title":"Novel and gram-scale green synthesis of flutamide","volume":"36","author":"Bandgar","year":"2006","journal-title":"Synthetic Commun."},{"key":"10.1016\/j.bioorg.2023.106998_b0205","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2174\/1389557522666220919125817","article-title":"Dehydroepiandrosterone (DHEA): pharmacological effects and potential therapeutic application","volume":"23","author":"Nenezic","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106998_b0210","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0039-128X(99)00027-6","article-title":"Testosterone sulfotransferase: evidence in the guinea pig that this reaction is carried out by 3 alpha-hydroxysteroid sulfotransferase","volume":"64","author":"Park","year":"1999","journal-title":"Steroids"},{"key":"10.1016\/j.bioorg.2023.106998_b0215","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Bicalutamide","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106998_b0220","unstructured":"Wass JA, Stewart PM (28 July 2011). Oxford Textbook of Endocrinology and Diabetes. OUP Oxford. pp. 1625\u2013. ISBN 978-0-19-923529-2. Archived from the original on 11 May 2016."},{"key":"10.1016\/j.bioorg.2023.106998_b0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003088-200443130-00003","article-title":"Bicalutamide: clinical pharmacokinetics and metabolism","volume":"43","author":"Cockshott","year":"2004","journal-title":"Clin. Pharmacokine."},{"key":"10.1016\/j.bioorg.2023.106998_b0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003495-200666060-00007","article-title":"Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer","volume":"66","author":"Wellington","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2023.106998_b0235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/GRF.0000000000000396","article-title":"Gender-affirming hormone therapy for transgender females","volume":"61","author":"Randolph","year":"2018","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.bioorg.2023.106998_b0240","first-page":"88","article-title":"Insights of priapism mechanism and rationale treatment for recurrent priapism, Asian","volume":"10","author":"Yuan","year":"2008","journal-title":"J. Androl."},{"key":"10.1016\/j.bioorg.2023.106998_b0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/0929867003375371","article-title":"Androgen receptor antagonists (antiandrogens): structure-activity relationships","volume":"7","author":"Singh","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106998_b0250","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-199834050-00005","article-title":"Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer","volume":"34","author":"Mahler","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2023.106998_b0255","unstructured":"P. Francesco, P. Roberta. A process for the preparation and purification of bicalutamide. WO2007039127A1."},{"key":"10.1016\/j.bioorg.2023.106998_b0260","unstructured":"E. Pizzatti, E. Vigano', M. Lussana, E. Landonio. Improved procedure for the synthesis of bicalutamide. 2006. US2006041161A1."},{"key":"10.1016\/j.bioorg.2023.106998_b0265","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1055\/s-2002-28508","article-title":"A two-step synthesis of the anti-cancer drug (R, S)-bicalutamide","volume":"2002","author":"James","year":"2002","journal-title":"Synthesis"},{"key":"10.1016\/j.bioorg.2023.106998_b0270","unstructured":"L. J. Denis, K. Griffiths, A. V. Kaisary, G. P. Murphy (1 March 1999). Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. pp. 280\u2013. ISBN 978-1-85317-422-3."},{"key":"10.1016\/j.bioorg.2023.106998_b0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0015-0282(16)60786-0","article-title":"Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease","volume":"52","author":"Couzinet","year":"1989","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.bioorg.2023.106998_b0280","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0022-4731(88)90023-4","article-title":"Clinical applications of antiandrogens","volume":"31","author":"Namer","year":"1988","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.bioorg.2023.106998_b0285","unstructured":"J. Perronnet, C. Bonne, P. Girault. 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl imidazolidines. 1977. DE2649925A1."},{"key":"10.1016\/j.bioorg.2023.106998_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0960-0760(94)90250-X","article-title":"RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism","volume":"48","author":"Battmann","year":"1994","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2023.106998_b0295","first-page":"455","article-title":"Synthesis of nilutamide and its analogue","volume":"35","author":"Qian","year":"2004","journal-title":"Chinese J. Pharma."},{"key":"10.1016\/j.bioorg.2023.106998_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/edrv-8-1-1","article-title":"Biological actions of androgens","volume":"8","author":"Mooradian","year":"1987","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2023.106998_b0305","first-page":"427","article-title":"The benefits and risks of testosterone replacement therapy: a review","volume":"5","author":"Bassil","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bioorg.2023.106998_b0310","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000176049","article-title":"Testosterone, bone and osteoporosis","volume":"37","author":"Tuck","year":"2009","journal-title":"Front. Horm. Res."},{"key":"10.1016\/j.bioorg.2023.106998_b0315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1373\/clinchem.2003.027565","article-title":"Serum testosterone in women as measured by an automated immunoassay and a RIA","volume":"50","author":"Torjesen","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bioorg.2023.106998_b0320","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1210\/jcem-27-5-686","volume":"27","author":"Southren","year":"1967","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2023.106998_b0325","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/jcem-25-11-1441","article-title":"Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes","volume":"25","author":"Southren","year":"1965","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2023.106998_b0330","unstructured":"Testosterone, Drugs and Lactation Database (LactMed\u00ae), National Institute of Child Health and Human Development, Bethesda (MD), 2006."},{"key":"10.1016\/j.bioorg.2023.106998_b0335","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/toxsci\/kfi005","article-title":"Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays","volume":"83","author":"Sonneveld","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bioorg.2023.106998_b0340","first-page":"157","article-title":"Cyproterone acetate in the therapy of prostate carcinoma","volume":"77","author":"Torri","year":"2005","journal-title":"Arch. Ital. Urol. Androl."},{"key":"10.1016\/j.bioorg.2023.106998_b0345","unstructured":"L. Yin, L. Liu, Y. Qu, H. Zhang, Q. Meng, S. Shi, R. Xu, Process and apparatus for manufacturing cyproterone acetate. 2018. CN108948121."},{"key":"10.1016\/j.bioorg.2023.106998_b0350","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Enzalutamide","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106998_b0355","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11912-013-0293-9","article-title":"Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer","volume":"15","author":"Menon","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2023.106998_b0360","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.13123","article-title":"Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer","volume":"117","author":"Schalken","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.bioorg.2023.106998_b0365","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1756287213490054","article-title":"Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer","volume":"5","author":"Saad","year":"2013","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.bioorg.2023.106998_b0370","unstructured":"R. Jain, Parasmal, R. Angelaud, A. Thompson, C. Lamberson, S. Greenfield. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds. 2011. WO2011106570A1."},{"key":"10.1016\/j.bioorg.2023.106998_b0375","unstructured":"V. Peddy, R. Boge, L.R. Madivada. Enzalutamide polymorphic forms and its preparation. 2014. WO2014041487A2."},{"key":"10.1016\/j.bioorg.2023.106998_b0380","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/jm901488g","article-title":"Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)","volume":"53","author":"Jung","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106998_b0385","unstructured":"D. Huanda, L. Jin, Y. Xinjie, L. Yanhua. Method for preparing enzalutamide. 2014. CN103910679A."},{"key":"10.1016\/j.bioorg.2023.106998_b0390","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1210\/clinem\/dgaa238","article-title":"A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men","volume":"105","author":"Swerdloff","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2023.106998_b0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2165\/00126839-200405060-00012","volume":"5","author":"Testosterone Undecanoate-Schering","year":"2004","journal-title":"Drugs R D"},{"key":"10.1016\/j.bioorg.2023.106998_b0400","doi-asserted-by":"crossref","unstructured":"S. Lachance, O. Dhingra, J. Bernstein, S. Gagnon, C. Savard, N. Pelletier, N. Boudreau, A. L\u00e9vesque, Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials, Future Sci. OA 1 (2015) Fso55.","DOI":"10.4155\/fso.15.55"},{"key":"10.1016\/j.bioorg.2023.106998_b0405","first-page":"3","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.bioorg.2023.106998_b0410","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/andr.12774","article-title":"Testosterone replacement therapy","volume":"8","author":"Barbonetti","year":"2020","journal-title":"Andrology"},{"key":"10.1016\/j.bioorg.2023.106998_b0415","unstructured":"H.B. Hou, C.G. Zheng, B.L. Zhu, J.X. Zheng, L. Liu, H. Fu, A preparation method of high purity testosterone undecanoate. 2022. CN114031661A."},{"key":"10.1016\/j.bioorg.2023.106998_b0420","first-page":"117","article-title":"Prasterone (Intrarosa) for Dyspareunia","volume":"99","author":"Hayes","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.bioorg.2023.106998_b0425","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2146\/ajhp060100","article-title":"Prasterone","volume":"63","author":"Kocis","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bioorg.2023.106998_b0430","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1021\/ja01311a036","article-title":"The preparation of dehydroandrosterone from cholesterol","volume":"57","author":"Wallis","year":"1935","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2023.106998_b0435","unstructured":"A. Fryszkowska, M.S. Quirmbach, S.S.C. Gorantla, S.R. Alieti, S.R. Poreddy, N.K.R. Dinne, U. Timmanna, V. Dahanukar. Processes for the preparation of dehydroepiandrosterone and its intermediates. 2014. WO2014188353A2."},{"key":"10.1016\/j.bioorg.2023.106998_b0440","unstructured":"L. Shen, Q. Zuo, F. Lei, L. Wu, S. Huang. Synthesis method for dehydroepiandrosterone. 2011. CN102212099A."},{"key":"10.1016\/j.bioorg.2023.106998_b0445","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Apalutamide","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106998_b0450","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bioorg.2023.106998_b0455","volume":"WO2007126765A2","author":"J.M. E, S.C. L, O. Samedy, T. Chris, W. John.","year":"2007","journal-title":"Androgen Receptor Modulator for Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases."},{"key":"10.1016\/j.bioorg.2023.106998_b0460","volume":"US20110003839A1","author":"Jung","year":"2011","journal-title":"Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Peceptor-Associated Diseases."},{"key":"10.1016\/j.bioorg.2023.106998_b0465","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.bioorg.2023.106998_b0470","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/TCRM.S6864","article-title":"Use of ethinylestradiol\/drospirenone combination in patients with the polycystic ovary syndrome","volume":"4","author":"Mathur","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bioorg.2023.106998_b0475","unstructured":"J. Mohr, K. Nickisch, Processing for producing of drospirenone (6\u03b2, 7\u03b2, 15\u03b2, 16\u03b2-dimethylene-3-oxo-17\u03b1-pregn-4-en-21,17-carbolactone, drsp) as well as 7\u03b1-(3-hydoxy-1-proply)-6\u03b2, 7\u03b2, 15\u03b2, 16\u03b2-dimethylene-5\u03b2-androstane-3\u03b2, 5,17\u03b2-triol (ZK 92836) and 6\u03b2, 7\u03b2, 15\u03b2, 16\u03b2-dimethylene-5\u03b2-hydroxy. 2005. US6933395B1."},{"key":"10.1016\/j.bioorg.2023.106998_b0480","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Darolutamide","year":"2012"},{"key":"10.1016\/j.bioorg.2023.106998_b0485","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1586\/14737140.2015.1081566","article-title":"ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer","volume":"15","author":"Fizazi","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2023.106998_b0490","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1358\/dot.2020.56.3.3110574","article-title":"Darolutamide for treatment of castration-resistant prostate cancer","volume":"56","author":"Rhea","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.bioorg.2023.106998_b0495","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.2147\/OTT.S197244","article-title":"Darolutamide for castration-resistant prostate cancer","volume":"12","author":"Chaplin","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bioorg.2023.106998_b0500","volume":"US8975254B2","author":"Wohlfahrt","year":"2015","journal-title":"Androgen Receptor Modulating Compounds."},{"key":"10.1016\/j.bioorg.2023.106998_b0505","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s40265-020-01417-6","article-title":"Clascoterone: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2023.106998_b0510","first-page":"197","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro","volume":"18","author":"Rosette","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.bioorg.2023.106998_b0515","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","volume":"18","author":"Rosette","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.bioorg.2023.106998_b0520","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","article-title":"Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris","volume":"83","author":"Eichenfield","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bioorg.2023.106998_b0525","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1016\/j.tetlet.2008.05.086","article-title":"Lipase-catalyzed preparation of corticosteroid 17\u03b1-esters endowed with antiandrogenic activity","volume":"49","author":"Ferraboschi","year":"2008","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2023.106998_b0530","doi-asserted-by":"crossref","first-page":"e24880","DOI":"10.1002\/jcla.24880","article-title":"Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: report of four cases and review of the literature","volume":"37","author":"Yang","year":"2023","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bioorg.2023.106998_b0535","volume":"US9216957B2","author":"Tong","year":"2015","journal-title":"Androgen Receptor Antagonists and Uses Thereof."},{"key":"10.1016\/j.bioorg.2023.106998_b0540","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-022-01831-y","article-title":"Rezvilutamide: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2023.106998_b0545","unstructured":"L. Zhong, Z.J. Qiu, Y.X. Cao, Y. Lu, A preparation method for imidazoline derivatives. 2022. CN113929628A."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:49:46Z","timestamp":1758617386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823006594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":109,"alternative-id":["S0045206823006594"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106998","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106998"}}